Krystal Net Interest Income from 2010 to 2024
| KRYS Stock | USD 181.96 4.48 2.52% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter 7.5 M | Current Value 7.6 M | Quarterly Volatility 2.7 M |
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 23.8 M, Interest Income of 23.8 M or Depreciation And Amortization of 6.2 M, as well as many indicators such as Price To Sales Ratio of 72.59, Dividend Yield of 0.0 or PTB Ratio of 4.11. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
Krystal | Net Interest Income |
Latest Krystal Biotech's Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Krystal Biotech over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Krystal Biotech's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Krystal Net Interest Income Regression Statistics
| Arithmetic Mean | 3,464,013 | |
| Coefficient Of Variation | 237.27 | |
| Mean Deviation | 5,494,421 | |
| Median | (7,000) | |
| Standard Deviation | 8,218,947 | |
| Sample Variance | 67.6T | |
| Range | 26.9M | |
| R-Value | 0.65 | |
| Mean Square Error | 42.3T | |
| R-Squared | 0.42 | |
| Significance | 0.01 | |
| Slope | 1,188,073 | |
| Total Sum of Squares | 945.7T |
Krystal Net Interest Income History
About Krystal Biotech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Krystal Biotech income statement, its balance sheet, and the statement of cash flows. Krystal Biotech investors use historical funamental indicators, such as Krystal Biotech's Net Interest Income, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may use each financial statement separately, they are all related. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Krystal Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Krystal Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Krystal Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 22.6 M | 23.8 M |
Pair Trading with Krystal Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krystal Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Krystal Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krystal Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krystal Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krystal Biotech to buy it.
The correlation of Krystal Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krystal Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krystal Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Krystal Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.